EQL Pharma Balance Sheet Health
Financial Health criteria checks 3/6
EQL Pharma has a total shareholder equity of SEK197.9M and total debt of SEK148.2M, which brings its debt-to-equity ratio to 74.9%. Its total assets and total liabilities are SEK423.3M and SEK225.4M respectively. EQL Pharma's EBIT is SEK47.7M making its interest coverage ratio 5.9. It has cash and short-term investments of SEK11.8M.
Key information
74.9%
Debt to equity ratio
SEK 148.22m
Debt
| Interest coverage ratio | 5.9x |
| Cash | SEK 11.83m |
| Equity | SEK 197.89m |
| Total liabilities | SEK 225.41m |
| Total assets | SEK 423.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7JK's short term assets (SEK232.7M) exceed its short term liabilities (SEK186.9M).
Long Term Liabilities: 7JK's short term assets (SEK232.7M) exceed its long term liabilities (SEK38.5M).
Debt to Equity History and Analysis
Debt Level: 7JK's net debt to equity ratio (68.9%) is considered high.
Reducing Debt: 7JK's debt to equity ratio has increased from 0% to 74.9% over the past 5 years.
Debt Coverage: 7JK's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 7JK's interest payments on its debt are well covered by EBIT (5.9x coverage).